What does Zydelig treat?
What does Zydelig treat?
Zydelig is a prescription medicine used to treat people with: • Chronic Lymphocytic Leukemia (CLL) in combination with rituximab when CLL comes back after prior cancer treatment and when rituximab treatment alone may be used due to other health problems.
Who owns Zydelig?
Zydelig FDA Approval History Company: Gilead Sciences, Inc.
How is Zydelig administered?
The recommended maximum starting dose of Zydelig is 150 mg administered orally twice daily. Zydelig can be taken with or without food. Tablets should be swallowed whole. Continue treatment until disease progression or unacceptable toxicity.
Does nefazodone cause weight gain?
Unlike the SSRI antidepressants, nefazodone associated with minimal weight gain and minimal sexual side effects. In addition, the reported activation of mania/hypomania may be lower with nefazodone than with some other antidepressants in bipolar patients.
Why is nefazodone being discontinued?
Reason for posting: Because of concerns of hepatotoxicity, the sale of the antidepressant nefazodone hydrochloride (Serzone) will be discontinued by the manufacturer effective Nov. 27, 2003.
What kind of cancer can Zydelig be used for?
The European Medicines Agency noted that data from the main studies showed high response rates with Zydelig in patients with chronic lymphocytic leukaemia and follicular lymphoma. Zydelig was also effective in chronic lymphocytic leukaemia patients whose cancer cells have the 17p deletion or TP53 mutation, who usually have a poor outcome.
When to re-initiation of Zydelig in Grade 3?
If the event recurs, treatment with Zydelig must be withheld until the values return to Grade 1 or less, after which re-initiation at 100 mg twice daily may be considered at the discretion of the physician (see sections 4.4 and 4.8). Treatment with Zydelig must be withheld in the event of Grade 3 or 4 diarrhoea/colitis.
Are there any side effects to taking Zydelig?
Side effects reported with Zydelig are carefully evaluated and any necessary action taken to protect patients. Zydelig received a marketing authorisation valid throughout the EU on 18 September 2014. This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines.
When to use Zydelig in combination with rituximab?
Zydelig is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): • who have received at least one prior therapy (see section 4.4), or • as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies (see section 4.4).
